Q-omics provides the consensus-scored CYB5R1 profile across patient tissues and cancer cell-line models. CYB5R1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYB5R1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CYB5R1 protein abundance shows 25,036 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KICH, and LUAD as cancer lineages where CYB5R1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB5R1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB5R1 survival associations across molecular data types. CYB5R1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB5R1 RNA expression–survival associations across cancer types. High CYB5R1 expression shows unfavorable associations in MESO and LGG, but favorable associations in KIRC, SARC, DLBC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYB5R1 RNA expression.
This table summarizes CYB5R1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CYB5R1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB5R1 shows lower tumor expression in KICH, THCA and STAD and higher tumor expression in LIHC, HNSC and BRCA. The KICH box plot shows higher CYB5R1 RNA expression in normal versus tumor tissue (log2 FC = −1.098, t-test p < 0.001).
This table shows molecular features associated with CYB5R1 in patient tissues and cancer cell lines. In patient samples, CYB5R1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CYB5R1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
